Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 116   

Articles published

JNJ 102.26 +0.06 (0.06%)
price chart
Johnson & Johnson Seeks Patent on Electronic Contact Lenses
As we've seen a lot recently, Johnson & Johnson patent applications have been focused on the development of electronic components for contact lenses.
Investors Sold Johnson & Johnson For All the Wrong Reasons
On Tuesday, health care conglomerate Johnson & Johnson (NYSE: JNJ ) reported its fourth-quarter and full-year earnings results.
J&J Beefing Up Device Product Pipeline  Medical Device and Diagnostics Industry
Johnson & Johnson's $7.2 billion claim against Boston Scientific now with US ...
NEW YORK (Reuters) - For more than eight years, Johnson & Johnson <JNJ.N> has pursued billions of dollars in damages against Boston Scientific Corp <BSX.
Johnson & Johnson (JNJ) Stock Lower Today After Goldman Downgrade
"We rate JOHNSON & JOHNSON (JNJ) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate.
Earnings Preview: Johnson & Johnson Q4 2014 (JNJ)  Seeking Alpha
Johnson & Johnson Given New $103.00 Price Target at Barclays (JNJ)  Dakota Financial News
Generating $100 A Month From Johnson & Johnson
If you invest $5,500 in Johnson & Johnson today, this would buy you about 51 shares or roughly $152 in expected income during 2015 -- just an eighth of the way to your goal.
Johnson & Johnson Ebola vaccine gets 100 million euro boost
Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.
Johnson & Johnson Announces Formation of Ebola Vaccine Development ...  PR Newswire (press release)
Johnson & Johnson (JNJ) Ebola Vaccine Receives $115M Boost For Human ...  International Business Times
Johnson & Johnson: 'Slightly Overvalued' Is No Reason To Sell (JNJ)
Recently an author indicated that Johnson & Johnson was slightly overvalued, further suggesting this would be a reason to sell.
15 Numbers That Will Make Johnson & Johnson Investors Giddy
If you expected earth-shattering news about a new development from Johnson & Johnson (NYSE: JNJ ) at the JP Morgan Healthcare Conference on Monday, you were disappointed.
Future still hazy for Johnson & Johnson's Ft. Washington factory
Johnson & Johnson has been a long-term moneymaker, and it said Tuesday that its full-year profit for 2014 rose 18 percent, but the last few months were less profitable for the health-care giant.
Ebola vaccine on its way to West Africa, Johnson & Johnson says
NEW BRUNSWICK - Johnson & Johnson has started to administer the first Ebola vaccine doses to volunteers, as part of a clinical trial which could reach millions over the course of this year, the New Jersey-based company announced today.
New Jersey-Based Johnson & Johnson Begins Testing Ebola Vaccine  CBS Local
Johnson & Johnson starts human testing of potential Ebola vaccine  Philadelphia Business Journal
Related articles »